Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flumatinib for TKI-resistant or intolerant Ph+ acute lymphoblastic leukemia
ChiCTR2000034199Phase 4Not yet recruiting
- Sponsor
- Sichuan Provincial People's Hospital
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Flumatinib in acute lymphoblastic leukemia (ALL), sponsored by Sichuan Provincial People's Hospital. Primary endpoints: complete remission rate, minimal residual disease and 5 more. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
Flumatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2000034199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034199.